Publications by authors named "C Silvain"
Background: In cirrhotic patients, portal hypertension increases mortality after surgery. We evaluated the impact of pre-operative transjugular intrahepatic portosystemic shunt (TIPS) on the outcomes of bariatric surgery in cirrhosis.
Methods: Multicentric retrospective cohort.
Article Synopsis
- Relapse after stopping immunosuppression treatment is common in Autoimmune Hepatitis (AIH) patients, and there's a need for better non-invasive biomarkers to predict this risk.
- The study analyzed blood samples from 58 active AIH patients, 56 in remission, and 31 with NASH, focusing on the levels of activated T cell subsets and the cytokine BAFF.
- Results showed that increased frequencies of certain activated T cells and high BAFF levels in remission patients were strongly linked to a higher chance of relapse after treatment withdrawal, suggesting these could serve as useful biomarkers for monitoring AIH.
Article Synopsis
- A study examined the risk of new thrombotic events in patients with non-cirrhotic portal vein thrombosis (NCPVT) linked to local factors after stopping anticoagulation therapy.
- Out of 154 patients assessed, a significant portion had high-risk prothrombotic factors, with new thrombotic events occurring in 17 patients during a median follow-up of 52 months.
- The results suggest that high-risk factors increase the likelihood of new thrombosis, while continuous anticoagulation treatment may reduce these risks effectively.
Article Synopsis
- The ELITor study analyzed real-world data from the CHIEF cohort to understand treatment patterns and patient characteristics for unresectable hepatocellular carcinoma in France, focusing on sociodemographic, clinical, and quality of life factors.
- A total of 367 patients were included, with most presenting at advanced BCLC C stage and a high prevalence of cirrhosis; alcohol was identified as the main cause of the disease.
- Results showed that tyrosine-kinase inhibitors were the most common systemic treatment, and patients receiving atezolizumab plus bevacizumab demonstrated better health statuses, although many experienced a decline in health quality post-treatment.
Article Synopsis
- * Conducted over a year, the research involved 1501 patients without known chronic liver disease; 33.6% of these showed positive signs for fibrosis, leading to further testing and specialist referrals.
- * The findings suggest that using these simple ultrasound indicators can effectively identify hepatic fibrosis in the general population, resulting in appropriate referrals for further evaluation and treatment.